These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 20164655

  • 1. Time to move to targeted drugs in biliary tract cancer?
    Louvet C, Tournigand C.
    Onkologie; 2010; 33(1-2):10-1. PubMed ID: 20164655
    [No Abstract] [Full Text] [Related]

  • 2. A phase II study of uracil-tegafur plus doxorubicin and prognostic factors in patients with unresectable biliary tract cancer.
    Furuse J, Okusaka T, Ohkawa S, Nagase M, Funakoshi A, Boku N, Yamao K, Yamaguchi T, Sato T.
    Cancer Chemother Pharmacol; 2009 Dec; 65(1):113-20. PubMed ID: 19404641
    [Abstract] [Full Text] [Related]

  • 3. Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.
    Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T, Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract.
    Cancer; 2002 Oct 15; 95(8):1685-95. PubMed ID: 12365016
    [Abstract] [Full Text] [Related]

  • 4. Gall bladder cancer, extrahepatic bile duct cancer and ampullary carcinoma in New Zealand: Demographics, pathology and survival.
    Koea J, Phillips A, Lawes C, Rodgers M, Windsor J, McCall J.
    ANZ J Surg; 2002 Dec 15; 72(12):857-61. PubMed ID: 12485219
    [Abstract] [Full Text] [Related]

  • 5. Imatinib mesylate for palliative second-line treatment of advanced biliary tract cancer: a bicentric phase II study.
    Roth A, Schleyer E, Schoppmeyer K, Kluge R, Wittekind C, Mössner J, Wiedmann M.
    Onkologie; 2011 Dec 15; 34(8-9):469-70. PubMed ID: 21934349
    [No Abstract] [Full Text] [Related]

  • 6. Phase II trial of combination chemotherapy with gemcitabine, 5-fluorouracil and cisplatin for advanced cancers of the bile duct, gallbladder, and ampulla of Vater.
    Sohn BS, Yuh YJ, Kim KH, Jeon TJ, Kim NS, Kim SR.
    Tumori; 2013 Dec 15; 99(2):139-44. PubMed ID: 23748804
    [Abstract] [Full Text] [Related]

  • 7. Early phase II study of uracil-tegafur plus doxorubicin in patients with unresectable advanced biliary tract cancer.
    Furuse J, Okusaka T, Funakoshi A, Yamao K, Nagase M, Ishii H, Nakachi K, Ueno H, Ikeda M, Morizane C, Horikawa Y, Mizuno N.
    Jpn J Clin Oncol; 2006 Sep 15; 36(9):552-6. PubMed ID: 16887837
    [Abstract] [Full Text] [Related]

  • 8. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F, Marino D, Cereda S, Filippi R, Belli C, Spadi R, Nasti G, Montano M, Amatu A, Aprile G, Cagnazzo C, Fasola G, Siena S, Ciuffreda L, Reni M, Aglietta M.
    Cancer; 2016 Feb 15; 122(4):574-81. PubMed ID: 26540314
    [Abstract] [Full Text] [Related]

  • 9. Preliminary experience of cetuximab in the treatment of advanced-stage biliary tract cancer.
    Chang PY, Cheng MF, Lee HS, Hsieh CB, Yao NS.
    Onkologie; 2010 Feb 15; 33(1-2):45-7. PubMed ID: 20164661
    [Abstract] [Full Text] [Related]

  • 10. Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC).
    Ji JH, Song HN, Kim RB, Oh SY, Lim HY, Park JO, Park SH, Kim MJ, Lee SI, Ryou SH, Hwang IG, Jang JS, Kim HJ, Choi JY, Kang JH.
    Jpn J Clin Oncol; 2015 Mar 15; 45(3):256-60. PubMed ID: 25628352
    [Abstract] [Full Text] [Related]

  • 11. Clinical presentation and management of intrahepatic cholangiocarcinoma.
    Farges O, Fuks D.
    Gastroenterol Clin Biol; 2010 Mar 15; 34(3):191-9. PubMed ID: 20202770
    [No Abstract] [Full Text] [Related]

  • 12. BINGO: targeted therapy for advanced biliary-tract cancer.
    Valle JW.
    Lancet Oncol; 2014 Jul 15; 15(8):778-80. PubMed ID: 24852117
    [No Abstract] [Full Text] [Related]

  • 13. [Current diagnostics and therapy for carcinomas of the biliary tree and gallbladder].
    Wiedmann M, Schoppmeyer K, Witzigmann H, Hauss J, Mössner J, Caca K.
    Z Gastroenterol; 2005 Mar 15; 43(3):305-15. PubMed ID: 15765304
    [Abstract] [Full Text] [Related]

  • 14. Amplification and overexpression of c-erbB-2, epidermal growth factor receptor, and c-met in biliary tract cancers.
    Nakazawa K, Dobashi Y, Suzuki S, Fujii H, Takeda Y, Ooi A.
    J Pathol; 2005 Jul 15; 206(3):356-65. PubMed ID: 15892172
    [Abstract] [Full Text] [Related]

  • 15. Capecitabine plus cisplatin as first-line chemotherapy for advanced biliary tract cancer: a retrospective single-center study.
    Woo SM, Lee WJ, Han SS, Park SJ, Kim TH, Koh YH, Kim HB, Hong EK, Park JW, Kim CM.
    Chemotherapy; 2012 Jul 15; 58(3):225-32. PubMed ID: 22831988
    [Abstract] [Full Text] [Related]

  • 16. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
    Song BG, Park JK, Kim HS, Kim K, Park JK, Lee KH, Lee KT, Lee JK.
    Scand J Gastroenterol; 2019 Jun 15; 54(6):740-745. PubMed ID: 31136212
    [Abstract] [Full Text] [Related]

  • 17. Oral capecitabine for the treatment of hepatocellular carcinoma, cholangiocarcinoma, and gallbladder carcinoma.
    Patt YZ, Hassan MM, Aguayo A, Nooka AK, Lozano RD, Curley SA, Vauthey JN, Ellis LM, Schnirer II, Wolff RA, Charnsangavej C, Brown TD.
    Cancer; 2004 Aug 01; 101(3):578-86. PubMed ID: 15274071
    [Abstract] [Full Text] [Related]

  • 18. Revolutionizing anti-HER2 therapies for extrahepatic cholangiocarcinoma and gallbladder cancer: Current advancements and future perspectives.
    Ten Haaft BH, Pedregal M, Prato J, Klümpen HJ, Moreno V, Lamarca A.
    Eur J Cancer; 2024 Mar 01; 199():113564. PubMed ID: 38266541
    [Abstract] [Full Text] [Related]

  • 19. Response to cetuximab and gemcitabine-oxaliplatin in an advanced case of intrahepatic cholangiocarcinoma.
    Bralet MP, Bellin MF, Guettier C, Adam R, Paule B.
    Clin Oncol (R Coll Radiol); 2006 Jun 01; 18(5):426. PubMed ID: 16817335
    [No Abstract] [Full Text] [Related]

  • 20. Molecular Characterization of Biliary Tract Cancer Predicts Chemotherapy and Programmed Death 1/Programmed Death-Ligand 1 Blockade Responses.
    Yoon JG, Kim MH, Jang M, Kim H, Hwang HK, Kang CM, Lee WJ, Kang B, Lee CK, Lee MG, Chung HC, Choi HJ, Park YN.
    Hepatology; 2021 Oct 01; 74(4):1914-1931. PubMed ID: 33884649
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.